Get the Stockscreener App
64.84
15.30%
8.845
Nektar Therapeutics stock is traded at $64.84, with a volume of 3.32M.
It is up +15.30% in the last 24 hours and up +62.60% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$56.00
Open:
$59
24h Volume:
3.32M
Relative Volume:
3.61
Market Cap:
$1.32B
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-44.41
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
+71.55%
1M Performance:
+62.60%
6M Performance:
+187.36%
1Y Performance:
+9,636%
1-Day Range:
$58.95
$67.94
1-Week Range:
$34.47
$67.94
52-Week Range:
$0.432
$67.94
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
64.84 | 1.14B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.00 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.48 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.65 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.88 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.75 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Initiated | Citigroup | Buy |
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Nektar Stock Soars Amid Promising Developments and Analyst Upgrades - StocksToTrade
Nektar seeks US$300m for promising eczema drug - ifr-logo
Nektar Therapeutics stock hits 52-week high at 66.97 USD - Investing.com
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
BTIG Lifts Nektar Price Target Amidst Promising Atopic Dermatitis Treatment - StocksToTrade
Nektar Therapeutics (NKTR) Shares Surge on $300M Public Offering Announcement - GuruFocus
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage - BioSpace
Nektar Therapeutics stock pops on $300M equity offering - MSN
Nektar Shares Surge On Phase IIb Rezpeg Atopic Dermatitis Data - Citeline News & Insights
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win - Yahoo Finance
Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Magazine
Nektar Therapeutics (NKTR) stock jumps again premarket after 51% surge; $300 million offering in focus - Bez Kabli
Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 - Yahoo Finance
BTIG Maintains Buy on Nektar Therapeutics (NKTR) Feb 2026 - Meyka
Nektar Therapeutics (NKTR) Launches $300M Stock Offering - GuruFocus
Nektar Therapeutics stock price target raised to $151 by BTIG - Investing.com UK
Nektar Therapeutics announces $300 million public offering By Investing.com - Investing.com Nigeria
Nektar reports positive long-term data for atopic dermatitis drug By Investing.com - Investing.com Nigeria
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Nektar Therapeutics announces $300 million public offering - Investing.com
Maintenance results boost Nektar's case for IL-2 agonist in atopic dermatitis - FirstWord Pharma
Nektar Therapeutics launches $300 mln equity offering after stock soars - TradingView
Double Trouble For Dupixent? Biotechs Fly On Eczema Tests. - Investor's Business Daily
Nektar Therapeutics Announces Proposed Public Offering - PR Newswire
Nektar Therapeutics (NKTR) Receives Boost with Analyst PT Raise | NKTR Stock News - GuruFocus
Nektar Therapeutics (NKTR) Analyst Rating Update: Price Target R - GuruFocus
Nektar Therapeutics stock price target raised to $151 by BTIG By Investing.com - Investing.com India
William Blair upgrades Nektar Therapeutics stock rating to Outperform By Investing.com - Investing.com UK
Biotech Stock Nektar Therapeutics (Nasdaq: NKTR) Makes Top Gainer List on News of REZOLVE-AD study - Investorideas.com
William Blair Upgrades Nektar Therapeutics(NKTR.US) to Buy Rating - 富途牛牛
Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study - BioPharma Dive
William Blair upgrades Nektar Therapeutics stock rating to Outperform - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Upgraded by William Blair to Outperform Rating - MarketBeat
Nektar’s Investor Call Stirs Market Interest on Rezpegaldesleukin Study - StocksToTrade
Nektar Therapeutics (NKTR) PT Raised to $151 at BTIG - StreetInsider
Nektar (NKTR) Upgraded as Rezpeg Shows Promising Long-Term Resul - GuruFocus
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis - HCPLive
Nektar eyes late-stage program for eczema therapy after positive mid-stage data - MSN
Nektar Therapeutics Stock Is Trending Tuesday: What's Going On? - Benzinga
Rezpegaldesleukin Shows Deepening Response and Long-Term Durability in 52-Week AD Trial - Dermatology Times
Nektar Therapeutics Set to Discuss New Study Results - timothysykes.com
William Blair Upgrades Nektar Therapeutics (NKTR) to Outperform - StreetInsider
Nektar eczema asset 'checked all of the boxes' in phase 2 - Fierce Biotech
Nektar Therapeutics (NKTR) Surges on Positive Trial Data for Eczema Treatment - GuruFocus
Nektar Expands with Enhanced Meeting Calendar and Strategic Engagements - StocksToTrade
Evommune reports positive mid-stage data for eczema drug - statnews.com
H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $165 - 富途牛牛
Nektar stock up on trial data for eczema drug (NKTR:NASDAQ) - Seeking Alpha
Nektar Advances Rezpegaldesleukin After Positive Phase 2b Data - TipRanks
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.50%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):